What is HC Wainwright’s Forecast for TSE:ONC Q1 Earnings?

Oncolytics Biotech Inc. (TSE:ONC) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Oncolytics Biotech in a research report issued to clients and investors on Wednesday, October 29th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.10) per share for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.08) EPS.

Separately, Lake Street Capital raised shares of Oncolytics Biotech to a “strong-buy” rating in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Oncolytics Biotech Price Performance

The firm has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. Oncolytics Biotech has a 1 year low of C$0.44 and a 1 year high of C$2.08. The stock’s 50 day simple moving average is C$14.66 and its two-hundred day simple moving average is C$5.79. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.